Order Article Reprints

Dannehl D, Engler T, Volmer LL, Tegeler CM, Fusshoeller J, Gabrysch E, Eissler K, Seller A, Grischke E-M, Hahn M, et al. Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers. Cancers. 2023; 15(15):3847. https://doi.org/10.3390/cancers15153847

Dannehl, Dominik, Tobias Engler, Léa Louise Volmer, Christian Martin Tegeler, Julia Fusshoeller, Emma Gabrysch, Kenneth Eissler, Anna Seller, Eva-Maria Grischke, Markus Hahn, and et al. 2023. "Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers" Cancers 15, no. 15: 3847. https://doi.org/10.3390/cancers15153847

Dannehl, D., Engler, T., Volmer, L. L., Tegeler, C. M., Fusshoeller, J., Gabrysch, E., Eissler, K., Seller, A., Grischke, E.-M., Hahn, M., Gruber, I., Schochter, F., Pfister, K., Veselinovic, K., Leinert, E., Rack, B., Fink, V., Janni, W., Brucker, S. Y., ... Schäffler, H. (2023). Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers. Cancers, 15(15), 3847. https://doi.org/10.3390/cancers15153847